You are here: Home: Meet The Professors Vol. 4 Issue 1: Faculty Disclosures

Faculty Affiliations

	Rowan T Chlebowski, MD, PhD Professor of Medicine David Geffen School of Medicine at UCLA Chief, Medical Oncology Harbor-UCLA Medical Center Torrance, California		John Mackey, MD Medical Oncologist, Cross Cancer Institute Associate Professor of Oncology, University of Alberta; Chair, Northern Alberta Breast Cancer Program; Director, Cancer International Research Group, Edmonton, Canada
	Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division Memorial Sloan-Kettering Cancer Center New York, New York		Vicente Valero, MD Professor of Medicine The University of Texas MD Anderson Cancer Center Houston, Texas

Medical Oncologist Community Panel

Howard R Abel, MD Fort Lauderdale, FL Mary Ann K Allison, MD Henderson, NV Alan B Astrow, MD New York, NY

Leon H Dragon, MD Highland Park, IL Allan Freedman, MD Snellville, GA Cheryl A Harth, MD Dallas, TX

Michel E Kuzur, MD Nashville, TN Scott D Lunin, MD Port Charlotte, FL William G Reeves, MD Youngstown, OH Michael A Schwartz, MD Miami Beach, FL

Sheryl R Simon, MD Sewickley, PA Brenda L Towell, MD Austin, TX Paul L Weinstein, MD Stamford, CT Richard S Zelkowitz, MD Norwalk, CT

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-theart education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Chlebowski — Consulting Fees: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals, Organon, Pfizer Inc. Dr Hudis — Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Kosan Biosciences, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc; Ownership Interest: Genomic Health Inc. Dr Mackey — Consulting Fees and Speaking Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Valero — Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals, Sanofi-Aventis; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.